Carboplatin and Bevacizumab for Recurrent Ependymoma
Status:
Completed
Trial end date:
2021-05-14
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of bevacizumab and
carboplatin can help to control recurrent ependymoma. The safety of this drug combination
will also be studied.